Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (JIL) AI Stock Analysis

2 Followers
DE:JIL

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

(Frankfurt:JIL)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Resilient ProfitabilityConsistently high gross and net margins indicate that the company has maintained effective economics across its pharmaceutical operations. Stable operating profitability provides a durable earnings base, supports internal reinvestment, and gives the business greater resilience if revenue growth remains uneven.
Negative Factors
Cooling Revenue MomentumThe progression from strong earlier expansion to flat, modest, and then slightly negative revenue growth signals weakening top-line momentum. If this pattern persists, it could limit operating leverage, reduce the pace of earnings expansion, and place greater importance on maintaining margins.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (JIL) vs. iShares MSCI Germany ETF (EWG)

-20%-10%0%10%20%30%40%50%60%DE:JIL+52.43%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 184.62M
Dividend Yield
―
Average Volume (3M)
2,088
Price to Earnings (P/E)
4.9
Beta (1Y)
0.05
Revenue Growth
-6.88%
EPS Growth
15.38%
Country
Germany
Employees
1,107
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio i...

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:JIL against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:2348HK:234874OutperformHKD 1.37B5.016.78%7.00%6.55%36.62%
HK:1061HK:106173OutperformHKD 1.13B4.3410.70%5.88%-0.74%-15.21%
HK:2161HK:216173OutperformHKD 1.27B6.1418.70%11.13%6.69%2.45%
HK:2633HK:263370OutperformHKD 1.75B6.0913.26%9.83%-0.47%-0.40%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:2561HK:256142NeutralHKD 1.37B-4.81-33.42%―――

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%50%DE:JILHK:1061HK:2161HK:2348HK:2633HK:2561Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:JIL and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:JILJilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H0.310.1153.92%
HK:1061Essex Bio-Technology 2.04-2.23-52.25%
HK:2161JBM (Healthcare) Ltd.1.53-1.15-42.87%
HK:2348Dawnrays Pharmaceutical Holdings Ltd.0.90-0.20-18.26%
HK:2633Jacobson Pharma Corporation Limited0.92-0.43-31.85%
HK:2561VISEN Pharmaceuticals12.46-20.94-62.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.